Gossamer Bio PROSERA Phase 3 Top Line Results Call Summary Company Overview - **Company**: Gossamer Bio, Inc. - **Focus**: Development of seralutinib for the treatment of pulmonary arterial hypertension (PAH) Key Industry and Company Insights Phase 3 Study Results - **Study Name**: PROSERA - **Objective**: Evaluate the efficacy of seralutinib in patients with PAH - **Primary Endpoint**: Change in six-minute walk distance at week 24 - **Results**: - Seralutinib showed a numerical improvement of approximately 13.3 meters compared to placebo (p-value = 0.032) - Did not meet the pre-specified statistical significance threshold of 0.025, thus considered not statistically significant [4][12][28] Subgroup Analysis - **Intermediate and High-Risk Subgroup**: - 234 patients defined by REVEAL Lite 2 risk score - Demonstrated a clinically meaningful improvement of 20 meters in six-minute walk distance (p-value = 0.0207) [5][17] - 3 out of 4 key secondary endpoints favored seralutinib with p-values below 0.0125 [5] Placebo Response - **Unexpected High Placebo Response**: - The placebo group showed a larger improvement than typically seen in PAH studies, which diluted the treatment effect [12][15] - Geographic differences noted, with North America showing more typical placebo responses compared to Latin America, where the placebo response was significantly higher [16][68] Safety Profile - **Adverse Events**: - Treatment-emergent adverse events (TEAEs) reported in 86.5% of seralutinib patients vs. 80.5% in placebo [24] - Most common TEAE was cough (37% in seralutinib vs. 13.7% in placebo) [25] - Liver enzyme elevations were noted, with 13% of seralutinib patients experiencing elevations ≥3 times the upper limit of normal [26][107] Strategic Decisions - **Enrollment Pause**: - Gossamer Bio decided to pause enrollment in the SERANATA Phase 3 study to focus resources on the PROSERA dataset and engage with the FDA [9][30] - **Next Steps**: - Further analysis of PROSERA data and discussions with regulators regarding the implications of the results [31] Commercial Opportunity - **Market Potential**: - Seralutinib is viewed as a meaningful opportunity in the PAH market, particularly for high-risk patients who face significant morbidity and mortality [30] Regulatory Considerations - **FDA Engagement**: - Gossamer Bio plans to present the PROSERA results to the FDA, emphasizing the unmet medical need in the high-risk population [56][100] Additional Important Insights - **Long-Term Efficacy**: - Data suggests that seralutinib may show improved efficacy over time, particularly in patients with more severe disease [15][70] - **Comparative Analysis**: - The treatment effect of seralutinib aligns well with other approved PAH therapies, especially in patients with higher baseline disease severity [20][21] This summary encapsulates the critical findings and strategic directions from the Gossamer Bio PROSERA Phase 3 results call, highlighting both the challenges and opportunities in the development of seralutinib for PAH treatment.

Core Viewpoint - Inhibikase Therapeutics, Inc. is advancing its lead product candidate IKT-001 towards a late-stage clinical trial for Pulmonary Arterial Hypertension (PAH) and reported financial results for Q3 2025, highlighting a significant increase in net loss and changes in cash position [1][4][3]. Financial Results - As of September 30, 2025, the company's cash, cash equivalents, and marketable securities totaled $77.3 million, down from $97.5 million as of December 31, 2024 [3]. - The net loss for Q3 2025 was $11.9 million, or $0.13 per share, compared to a net loss of $5.8 million, or $0.65 per share in Q3 2024. For the nine months ended September 30, 2025, the net loss was $35.5 million, or $0.40 per share, compared to a net loss of $15.4 million, or $2.03 per share for the same period in 2024 [4][14]. - Research and development expenses for Q3 2025 were $7.6 million, up from $4.2 million in Q3 2024. For the nine months ended September 30, 2025, R&D expenses totaled $23.4 million, which included a non-cash write-off of in-process R&D of $7.4 million [5]. - Selling, general and administrative expenses for Q3 2025 were $5.6 million, compared to $1.6 million in Q3 2024. For the nine months ended September 30, 2025, these expenses were $16.8 million, which included $1.0 million in severance expenses [6]. Recent Developments - The company plans to initiate a Phase 2b clinical study of IKT-001 in PAH during Q4 2025, with the trial expected to involve approximately 150 participants [2][8]. - The proposed IMPROVE-PAH trial will be a multi-center, randomized, double-blind, placebo-controlled study, with a primary efficacy endpoint of change in pulmonary vascular resistance at Week 26 [8]. - Timothy Pigot has been appointed as the Chief Commercial and Strategy Officer [8]. - The company is scheduled to present at the Jefferies Global Healthcare Conference in London on November 17, 2025 [8].